Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: PROCEDURE: Sentinel Lymph Node Biopsy (SLNB)|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)|BIOLOGICAL: Interleukin-2|DRUG: Nab-paclitaxel
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University